{"id":"diclofenac-omeprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL139","moleculeType":"Small molecule","molecularWeight":"296.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that blocks cyclooxygenase (COX) enzymes, reducing prostaglandin production and thereby decreasing inflammation, pain, and fever. Omeprazole is a proton pump inhibitor that irreversibly blocks H+/K+-ATPase in gastric parietal cells, significantly reducing gastric acid secretion. This combination is designed to provide NSAID efficacy while mitigating the gastrointestinal toxicity (ulcers, bleeding) associated with chronic NSAID use.","oneSentence":"Diclofenac inhibits prostaglandin synthesis to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:41.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis with gastric protection"},{"name":"Osteoarthritis with gastric protection"},{"name":"Ankylosing spondylitis with gastric protection"},{"name":"Acute pain conditions requiring NSAID therapy with gastroprotection"}]},"trialDetails":[{"nctId":"NCT06566794","phase":"NA","title":"KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2024-08-22","conditions":"Drug Interaction","enrollment":12},{"nctId":"NCT04766996","phase":"PHASE4","title":"PROUD Study - Preventing Opioid Use Disorders","status":"TERMINATED","sponsor":"Emory University","startDate":"2021-05-17","conditions":"Anesthesia, Opioid Use","enrollment":57},{"nctId":"NCT00141102","phase":"PHASE4","title":"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-10","conditions":"Osteoarthritis, Arthritis, Rheumatoid","enrollment":4484},{"nctId":"NCT01596647","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Advanced Solid Tumors, Excluding Breast Cancer","enrollment":39},{"nctId":"NCT03473665","phase":"PHASE4","title":"Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2018-03-01","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":9},{"nctId":"NCT02361619","phase":"PHASE1","title":"Dabigatran in an Interaction Probe Drug Cocktail","status":"COMPLETED","sponsor":"Turku University Hospital","startDate":"2015-02","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT01290380","phase":"PHASE1","title":"A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-02","conditions":"Solid Tumor Malignancies","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":151,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Diclofenac + Omeprazole","genericName":"Diclofenac + Omeprazole","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diclofenac inhibits prostaglandin synthesis to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers. Used for Rheumatoid arthritis with gastric protection, Osteoarthritis with gastric protection, Ankylosing spondylitis with gastric protection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}